

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Frederic Colland et al.

Confirmation No.: 2640

Serial No.: 10/520,712

Art Unit: 1614

Filed: December 22, 2005

Examiner: Laura B. Goddard

For: ***Use of Specified TCF Target Genes to  
Identify Drugs for the Treatment of  
Cancer, in Particular Colorectal Cancer, In  
which TCF/ $\beta$ -Catenin/WNT Signalling  
Plays a Central Role***

POWER OF ATTORNEY BY ASSIGNEE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R:

Kiadis Pharma, BV, owner of the entire right, title and interest in, to and under the invention listed above, by virtue of an Assignment from Semaia Pharmaceuticals BV recorded on June 19, 2007 at Reel 019451, Frame 0196, hereby appoints Morgan, Lewis & Bockius LLP, **Customer No. 67374**, and each of them, its attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Morgan, Lewis & Bockius LLP as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all future correspondence to the address associated with Customer No. 67374, Morgan, Lewis & Bockius LLP and direct all telephone calls to Morgan, Lewis & Bockius LLP at (415) 442-1000.

Date:

12/3/07

Assignee:

Kiadis Pharma, BV

Signature:



Typed Name:

M. Baubach

Position/Title:

CEO

Address:

Zernikepark 6-8  
9747 ZN Groningen  
The Netherlands